Skip to NavigationSkip to content

AstraZeneca’s Brilinta reduces the rate of stroke and death in patients with acute ischaemic stroke or transient ischaemic attack

Published on 16/07/20 at 11:29am

AstraZeneca’s Phase 3 THALES trial showed that Brilinta (ticagrelor) significantly reduced the rate of death or stroke in patients with acute ischaemic stroke or transient ischaemic attack (TIA).

The results were published in The New England Journal of Medicine, and patients took 90mg of Brilinta twice daily with aspirin for 30 days. This reduced the rate of the primary endpoint of stroke and death by 17% compared to aspirin alone in TIA patients. This was a statistically significant and a clinically meaningful reduction. Brilinta combined with aspiring also significantly reduced the rate of schaemic stroke by 21%, compared to aspirin alone up to day 30.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said: “Patients who had an acute ischaemic stroke or transient ischemic attack may experience a subsequent, potentially avoidable stroke. Results from the Phase III THALES trial confirm that aspirin plus Brilinta has the potential to be a new effective treatment option for these high-risk patients and we look forward to continuing discussions with regulatory authorities.”

The FDA accepted a New Drug Application and granted a Priority Review for Brilinta for TIA based on this Phase 3 trial. It is already approved in more than 110 countries for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.

Conor Kavanagh

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches